Kintor Pharma
HKEX:9939Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileOverview
Chinese biotech developing androgen receptor-targeted therapies for dermatology and oncology with multiple clinical-stage assets.
OncologyDermatology
Technology Platform
Focus on androgen receptor pathway modulation through small molecules including AR antagonists and AR-PROTAC degraders, complemented by biologic approaches including ALK-1 antibodies.
Opportunities
Significant market opportunity in androgenetic alopecia with KX-826's recent Phase III success, plus expansion into cosmetic raw materials through partnerships for KT-939.
Risk Factors
Heavy reliance on AR pathway targets creates concentration risk; facing intense competition in both dermatology and oncology markets from larger pharmaceutical companies.
Competitive Landscape
Competes with established dermatology companies in alopecia (like Pfizer's finasteride) and emerging biotechs in oncology; differentiation through AR-PROTAC technology and topical formulation expertise for KX-826.